NCM
SPRY icon

Nantahala Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Nantahala Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,596,504
Closed -$8.75M – 142
2023
Q4 		$8.75M Buy
1,596,504
+497,429
+45% +$2.18M 0.52% 43
2023
Q3 		$4.15M Buy
1,099,075
+918,978
+510% +$6.03M 0.35% 63
2023
Q2 		$1.21M Buy
+180,097
New +$1.2M 0.12% 87
2022
Q4 		– Sell
-1,249,863
Closed -$6.6M – 130
2022
Q3 		$6.6M Sell
1,249,863
-136,275
-10% -$672K 0.43% 51
2022
Q2 		$5.88M Buy
1,386,138
+472,541
+52% +$1.65M 0.29% 58
2022
Q1 		$3.15M Sell
913,597
-92,865
-9% -$404K 0.14% 76
2021
Q4 		$6.7M Sell
1,006,462
-220,169
-18% -$1.79M 0.24% 72
2021
Q3 		$12.2M Sell
1,226,631
-39,635
-3% -$977K 0.39% 56
2021
Q2 		$39.1M Buy
1,266,266
+274,024
+28% +$8.79M 1.11% 24
2021
Q1 		$42.7M Sell
992,242
-214,229
-18% -$10.1M 1.25% 24
2020
Q4 		$54.4M Buy
+1,206,471
New +$40.3M 1.69% 11

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management's SPRY Position: Q1 2024 in Review

Nantahala Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 1,596,504 shares — an estimated $8.75M sold.

Nantahala Capital Management first reported a position in SPRY in Q4 2020 and held it in 11 quarters. The position peaked at $54.4M in Q4 2020. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Nantahala Capital Management reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 1,596,504 ARS Pharmaceuticals shares in Q1 2024, an estimated $8.75M.
  • Nantahala Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Nantahala Capital Management's ARS Pharmaceuticals position peaked at $54.4M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.